Amylyx Pharmaceuticals is a clinical stage biotechnology company. Co. is developing therapies for amyotrophic lateral sclerosis (ALS) and a range of other neurodegenerative diseases, including Alzheimer's Disease, Wolfram syndrome, Parkinson's Disease, Huntington's Disease, Progressive Supranuclear Palsy, Multi-System Atrophy, primary lateral sclerosis, ischemic stroke, multiple sclerosis, Friedreich's ataxia, and Leigh's syndrome. Co. is pursuing commercialization of AMX0035, which is a drug candidate for patients with ALS. AMX0035 is a dual unfolded protein response-Bcl-2 Associated X-protein apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid. The AMLX average annual return since 2022 is shown above.
The Average Annual Return on the AMLX average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AMLX average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AMLX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|